1325 Preclinical activity and safety profile of JANX007, a novel PSMA-targeting tumor-activated T Cell engager for treatment of metastatic castration-resistant prostate cancer

DiRaimondo, Thomas; Budimir, Natalija; Shenhav, Simon; Wang, Hua; Cicchini, Vanessa; Jocic, Renee; Ma, Lei; Roup, Fabrece; Campbell, D C; Caffaro, Carolina E.; Aerni, Hans; Eskiocak, Uğur; Godfrey, Wayne R.; Winter, Charles H.; Nasoff, Marc; Gibson, Neil; Campbell, David; Salek-Ardakani, Shahram

doi:10.1136/jitc-2022-sitc2022.1325

Regular and Young Investigator Award Abstracts 2022

DOI: 10.1136/jitc-2022-sitc2022.1325

|View full text |Cite

1325 Preclinical activity and safety profile of JANX007, a novel PSMA-targeting tumor-activated T Cell engager for treatment of metastatic castration-resistant prostate cancer

Thomas DiRaimondo

Natalija Budimir

Simon Shenhav

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

1325 Preclinical activity and safety profile of JANX007, a novel PSMA-targeting tumor-activated T Cell engager for treatment of metastatic castration-resistant prostate cancer

Cited by 2 publications

References 0 publications

T-cell-engaging bispecific antibodies in cancer

T-cell-engaging bispecific antibodies in cancer

What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment

Contact Info

Product

Resources

About